scholarly journals Dietary vitamin B intake and the risk of esophageal cancer: a meta-analysis

2018 ◽  
Vol Volume 10 ◽  
pp. 5395-5410 ◽  
Author(s):  
Jun-Li Ma ◽  
Yan Zhao ◽  
Chen-Yang Guo ◽  
Hong-Tao Hu ◽  
Lin Zheng ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Meta Analysis ◽  
Dietary Vitamin ◽  
Vitamin B

scholarly journals A dose–response meta-analysis reveals an association between vitamin B12 and colorectal cancer risk

2015 ◽  
Vol 19 (8) ◽  
pp. 1446-1456 ◽  
Author(s):  
Nai-Hui Sun ◽  
Xuan-Zhang Huang ◽  
Shuai-Bo Wang ◽  
Yuan Li ◽  
Long-Yi Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dose Response ◽  
Meta Analysis ◽  
Dietary Vitamin ◽  
Vitamin B ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Total Vitamin ◽  
Linear Dose ◽  
Non Linear

AbstractObjectiveThe current meta-analysis evaluated the association between vitamin B12 intake and blood vitamin B12 level and colorectal cancer (CRC) risk.DesignThe PubMed and EMBASE databases were searched. A dose–response analysis was performed with generalized least squares regression, with the relative risk (RR) and 95 % CI as effect values.SettingThe meta-analysis included seventeen studies.SubjectsA total of 10 601 patients.ResultsThe non-linear dose–response relationship between total vitamin B12 intake and CRC risk was insignificant (P=0·690), but the relationship between dietary vitamin B12 intake and CRC risk was significant (P<0·001). Every 4·5 μg/d increment in total and dietary vitamin B12 intake was inversely associated with CRC risk (total intake: RR=0·963; 95 % CI 0·928, 0·999; dietary intake: RR=0·914; 95 % CI 0·856, 0·977). The inverse association between vitamin B12 intake and CRC risk was also significant when vitamin B12 intake was over a dosage threshold, enhancing the non-linear relationship. The non-linear dose–response relationship between blood vitamin B12 level and CRC risk was insignificant (P=0·219). There was an insignificant association between every 150 pmol/l increment in blood vitamin B12 level and CRC risk (RR=1·023; 95 % CI 0·881, 1·187).ConclusionsOur meta-analysis indicates that evidence supports the use of vitamin B12 for cancer prevention, especially among populations with high-dose vitamin B12 intake, and that the association between CRC risk and total vitamin B12 intake is stronger than between CRC risk and dietary vitamin B12 intake only.

scholarly journals Association between Dietary Vitamin E Intake and Esophageal Cancer Risk: An Updated Meta-Analysis

Nutrients ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 801 ◽  
Author(s):  
Lingling Cui ◽  
Li Li ◽  
Yalan Tian ◽  
Fan Xu ◽  
Tianyi Qiao
Keyword(s):  
Esophageal Cancer ◽  
Vitamin E ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Dietary Vitamin

scholarly journals Association between dietary vitamin C intake and risk of esophageal cancer: A dose-response meta-analysis

2015 ◽  
Vol 138 (8) ◽  
pp. 1843-1850 ◽  
Author(s):  
Yacong Bo ◽  
Yan Lu ◽  
Yan Zhao ◽  
Erjiang Zhao ◽  
Ling Yuan ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Vitamin C ◽  
Dose Response ◽  
Meta Analysis ◽  
Dietary Vitamin

scholarly journals Dietary Intake of Homocysteine Metabolism-Related B-Vitamins and the Risk of Stroke: A Dose-Response Meta-Analysis of Prospective Studies

2020 ◽  
Author(s):  
Liyun Chen ◽  
Qianwen Li ◽  
Xuexian Fang ◽  
Xinhui Wang ◽  
Junxia Min ◽  
...  
Keyword(s):  
Dietary Intake ◽  
Dose Response ◽  
Prospective Studies ◽  
Meta Analysis ◽  
B Vitamins ◽  
Dietary Vitamin ◽  
Vitamin B ◽  
Inverse Association ◽  
Vitamin B 12 ◽  
Reduced Risk

ABSTRACT Observational studies regarding the putative associations between dietary intake of homocysteine metabolism-related B-vitamins (vitamin B-6, folate, and vitamin B-12) and stroke risk have yielded inconsistent results. Thus, we conducted a systematic meta-analysis of prospective studies in order to examine the relation between the dietary (from diet and supplements) intake of these B-vitamins and the risk of stroke. PubMed and Web of Science were searched for relevant articles published through to 25 February, 2020, and RR of stroke in relation to dietary intake of vitamin B-6, folate, and vitamin B-12 were pooled using a random-effects model. Eleven publications of 12 prospective studies comprising 389,938 participants and 10,749 cases were included in the final analysis. We found that dietary intake of vitamin B-6 and folate were associated with a reduced risk of stroke, and this inverse association remained significant in studies with &gt;10 y of follow-up periods and among participants without a pre-existing stroke event. A dose-response analysis revealed a linear inverse association between folate and vitamin B-6 intake and the risk of stroke, with a pooled RR of 0.94 (95% CI: 0.90–0.98) and 0.94 (95% CI: 0.89–0.99) for each 100 μg/d increment in folate intake and 0.5 mg/d increment in vitamin B-6 intake, respectively. In contrast, we found no significant association between dietary vitamin B-12 intake and the risk of stroke, with an RR of 1.01 (95% CI: 0.97–1.06) per 3 μg/d increase. In conclusion, our findings suggest that increased intake of vitamin B-6 and folate is associated with a reduced risk of stroke, supporting the notion that increasing habitual folate and vitamin B-6 intake may provide a small but beneficial effect with respect to stroke.

scholarly journals The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review

2021 ◽  
Vol 28 ◽  
pp. 107327482199743
Author(s):  
Ke Chen ◽  
Xiao Wang ◽  
Liu Yang ◽  
Zheling Chen
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Survival Rate ◽  
Meta Analysis ◽  
Response Rates ◽  
Control Group ◽  
Term Survival ◽  
Long Term Survival ◽  
And Control

Background: Treatment options for advanced gastric esophageal cancer are quite limited. Chemotherapy is unavoidable at certain stages, and research on targeted therapies has mostly failed. The advent of immunotherapy has brought hope for the treatment of advanced gastric esophageal cancer. The aim of the study was to analyze the safety of anti-PD-1/PD-L1 immunotherapy and the long-term survival of patients who were diagnosed as gastric esophageal cancer and received anti-PD-1/PD-L1 immunotherapy. Method: Studies on anti-PD-1/PD-L1 immunotherapy of advanced gastric esophageal cancer published before February 1, 2020 were searched online. The survival (e.g. 6-month overall survival, 12-month overall survival (OS), progression-free survival (PFS), objective response rates (ORR)) and adverse effects of immunotherapy were compared to that of control therapy (physician’s choice of therapy). Results: After screening 185 studies, 4 comparative cohort studies which reported the long-term survival of patients receiving immunotherapy were included. Compared to control group, the 12-month survival (OR = 1.67, 95% CI: 1.31 to 2.12, P < 0.0001) and 18-month survival (OR = 1.98, 95% CI: 1.39 to 2.81, P = 0.0001) were significantly longer in immunotherapy group. The 3-month survival rate (OR = 1.05, 95% CI: 0.36 to 3.06, P = 0.92) and 18-month survival rate (OR = 1.44, 95% CI: 0.98 to 2.12, P = 0.07) were not significantly different between immunotherapy group and control group. The ORR were not significantly different between immunotherapy group and control group (OR = 1.54, 95% CI: 0.65 to 3.66, P = 0.01). Meta-analysis pointed out that in the PD-L1 CPS ≥10 sub group population, the immunotherapy could obviously benefit the patients in tumor response rates (OR = 3.80, 95% CI: 1.89 to 7.61, P = 0.0002). Conclusion: For the treatment of advanced gastric esophageal cancer, the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy was superior to that of chemotherapy or palliative care.

Sign in / Sign up

Export Citation Format

Share Document